Monashee Investment Management LLC Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Monashee Investment Management LLC purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 888,888 shares of the biotechnology company's stock, valued at approximately $2,204,000. Aclaris Therapeutics makes up about 0.3% of Monashee Investment Management LLC's holdings, making the stock its 25th largest position. Monashee Investment Management LLC owned approximately 1.24% of Aclaris Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Samsara BioCapital LLC increased its stake in shares of Aclaris Therapeutics by 242.6% in the 4th quarter. Samsara BioCapital LLC now owns 2,385,060 shares of the biotechnology company's stock worth $5,915,000 after acquiring an additional 1,688,889 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Aclaris Therapeutics during the fourth quarter worth about $327,000. Northern Trust Corp raised its stake in Aclaris Therapeutics by 37.7% during the fourth quarter. Northern Trust Corp now owns 175,175 shares of the biotechnology company's stock worth $434,000 after purchasing an additional 47,950 shares during the period. Decheng Capital LLC purchased a new position in Aclaris Therapeutics during the fourth quarter worth about $5,621,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $279,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS traded up $0.06 during trading on Friday, reaching $1.44. The stock had a trading volume of 668,869 shares, compared to its average volume of 1,184,085. The business's 50-day moving average price is $1.48 and its 200-day moving average price is $2.23. Aclaris Therapeutics, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The company has a market cap of $155.92 million, a P/E ratio of -2.77 and a beta of 0.53.

Wall Street Analyst Weigh In

Several analysts have recently commented on ACRS shares. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an "overweight" rating on the stock. Scotiabank started coverage on Aclaris Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Finally, StockNews.com downgraded Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.67.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.